# El papel de los iSGLT2 para coadyuvar en el control de la hipertensión arterial en la DM2
URL canonica: https://calculadoras.nmn.mx/infografias/papel-isglt2-coadyuvar-control-hipertension-arterial-dm2  
Tipo: INFOGRAFIA  
Audiencia: Profesionales de la salud  
Areas terapeuticas: Cardiometabolico  
Padecimientos: Diabetes mellitus tipo 2, Hipertensión arterial sistémica  
Fecha de publicacion: 2025-10-26T00:00:00.000Z  
Ultima actualizacion: 2026-04-17T18:35:31.000Z  
![El papel de los iSGLT2 para coadyuvar en el control de la hipertensión arterial en la DM2](https://apimedpoint.nmn.mx/uploads/contenidos/portadas/el_papel_de_los_isglt2.jpg)
## Resumen
## Contenido

## Referencias

- Cardiovascular disease and risk management: Standards of Care in Diabetes—2025. Diabetes Care, 2025, vol. 48, no Supplement_1, p. S207-S238.
- Chronic kidney disease and risk management: standards of care in diabetes—2025. Diabetes Care, 2025, vol. 48, no Supplement_1, p. S239-S251.
- Neal B., Perkovic V., Mahaffey K. W., De Zeeuw D., Fulcher G., et al. (ago 2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377(7), p. 644-657.
- Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016). Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, obesity & metabolism, 18(8), 783–794. [https://doi.org/10.1111/dom.12670](https://doi.org/10.1111/dom.12670)
- Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013). Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia, 56(12), 2582–2592. [https://doi.org/10.1007/s00125-013-3039-1](https://doi.org/10.1007/s00125-013-3039-1)
- Arnott, C., Neuen, B. L., Heerspink, H. J. L., Figtree, G. A., Kosiborod, M., Lam, C. S., Cannon, C. P., Rosenthal, N., Shaw, W., Mahaffey, K. W., Jardine, M. J., Perkovic, V., & Neal, B. (2020). The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International journal of cardiology, 318, 126–129. [https://doi.org/10.1016/j.ijcard.2020.06.011](https://doi.org/10.1016/j.ijcard.2020.06.011)